Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery

This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market

G Square acquires majority stake in Finnish surgical solutions leader Serres

Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits

Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding

iRegene’s Parkinson’s therapy gains FDA designation

The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases

Novo Nordisk deepens Aspect Biosystems alliance in push for curative diabetes cell therapies

Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies

Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half

The study evaluated patients with stage III/IV melanoma after complete tumor resection

Sigachi Industries achieves key R&D milestone in Cystic Fibrosis APIs

The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments

AGC Biologics powers commercial launch of its life-changing gene therapy for rare childhood immune disorder

Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector

Symeres rehires Jurgen Berendsen as CFO amid strategic growth push

Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade

IDT and Ansa Biotechnologies join forces to push limits of DNA synthesis

The collaboration aims to accelerate the delivery of challenging DNA motifs with speed, precision, and reliability